Australian Broker Call *Extra* Edition – Aug 16, 2022

This story features AUSTRALIAN CLINICAL LABS LIMITED, and other companies. For more info SHARE ANALYSIS: ACL

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

ACL   AQZ   ARF (2)   ARX   BRG   CBA (2)   CGC   CNI (2)   CSL   DXI   GNC   LOT   MGR   MNY   MYX   NCZ   NIC   NUF   OFX   QBE   SBM   UBI  

ACL    AUSTRALIAN CLINICAL LABS LIMITED

Healthcare services – Overnight Price: $4.87

Goldman Sachs rates ((ACL)) as Buy (1) –

Australian Clinical Labs' FY22 result missed consensus and Goldman Sachs' forecasts.

It was a thorny issue given the company guided on June that it would meet consensus, but consensus since rose, leaving the company to post a -5% miss.

A decline in covid volumes and business as usual activity in June proved the culprit, as was cost growth in consumables – up -70% compared with revenue growth of 48% – which crunched margins (as did the pooling of higher efficiency PCR specimens).

The broker notes July and August posted an improvement and notes management has outperformed peers, but forecasts continued falls in covid revenue.

Price target falls to $5.70 from $6.50. Buy rating reiterated given the retreat in the share price.

This report was published on August 10, 2022.

Target price is $5.70 Current Price is $4.87 Difference: $0.83
If ACL meets the Goldman Sachs target it will return approximately 17% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 19.00 cents and EPS of 34.00 cents.
At the last closing share price the estimated dividend yield is 3.90%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.32.

Forecast for FY24:

Goldman Sachs forecasts a full year FY24 dividend of 14.00 cents and EPS of 24.00 cents.
At the last closing share price the estimated dividend yield is 2.87%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.29.

Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

AQZ    ALLIANCE AVIATION SERVICES LIMITED

Transportation & Logistics – Overnight Price: $3.60

Wilsons rates ((AQZ)) as Market Weight (3) –

Alliance Aviation Services' FY22 result fell at the lower end of guidance as industry disruption further delayed the E190 deployment. Pre-tax profit outpaced Wilsons by 1% but earnings (EBITDA) missed by -4%.

While Wilsons appreciates the earnings potentials from the E190 deployment, the broker notes FY23 earnings are now starting from a lower point and suspects margins may be be challenged. Add to that the ongoing ACCC assessment of Qantas Airways' ((QAN)) take-over interest, and the broker finds it hard to get excited.

Market Weight rating retained. Target price is $3.43.

This report was published on August 11, 2022.

Target price is $3.43 Current Price is $3.60 Difference: minus $0.17 (current price is over target).
If AQZ meets the Wilsons target it will return approximately minus 5% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.58, suggesting upside of 27.3%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 17.60 cents and EPS of 27.00 cents.
At the last closing share price the estimated dividend yield is 4.89%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.33.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 27.8, implying annual growth of N/A.
Current consensus DPS estimate is 5.9, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 12.9.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 22.20 cents and EPS of 34.20 cents.
At the last closing share price the estimated dividend yield is 6.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.53.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 33.1, implying annual growth of 19.1%.
Current consensus DPS estimate is 14.6, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 10.9.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ARF    ARENA REIT

REITs – Overnight Price: $4.45

Jarden rates ((ARF)) as Underweight (4) –

Jarden views Arena REIT as a safe investment in the REIT sector, based on the conservative balance sheet, CPI linked rental growth and the pipeline of developments.

However, the analyst considers the 43% premium that Arena REIT is trading at, relative to the 12% upgraded NTA as at the 2H22, as high.

Jarden highlights potential upside risks to the NTA from the ongoing compression in cap rates, a Federal government with more emphasis on childcare and higher earnings growth, with negative risks from rising interest rates placing pressure on valuations.

Underweight maintained for Arena REIT. Target is reduced to $4.35 from $4.50.

This report was published on August 15, 2022.

Target price is $4.35 Current Price is $4.45 Difference: minus $0.1 (current price is over target).
If ARF meets the Jarden target it will return approximately minus 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.49, suggesting upside of 1.0%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 16.80 cents and EPS of 17.20 cents.
At the last closing share price the estimated dividend yield is 3.78%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.87.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 17.9, implying annual growth of -79.7%.
Current consensus DPS estimate is 17.5, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 24.9.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 17.90 cents and EPS of 18.30 cents.
At the last closing share price the estimated dividend yield is 4.02%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 24.32.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is N/A, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Moelis rates ((ARF)) as Sell (5) –

Following FY22 results for Arena REIT, Moelis lowers its earnings estimates after incorporating a higher cost of debt, and the target price slips to $3.83 from $3.86.

Management reported FY22 funds from operations (FFO) of 16.3cpu, with a dividend of 16.0cps, in line with guidance. Dividend guidance for FY23 is for 16.8cpu, which implies FFO of around 17.2cpu, explains the analyst.

While assets, management and lease structure are of high quality, in the broker's opinion, the Sell rating is unchanged on valuation grounds.

This report was published on August 12, 2022.

Target price is $3.83 Current Price is $4.45 Difference: minus $0.62 (current price is over target).
If ARF meets the Moelis target it will return approximately minus 14% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.49, suggesting upside of 1.0%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Moelis forecasts a full year FY23 dividend of 16.80 cents and EPS of 17.40 cents.
At the last closing share price the estimated dividend yield is 3.78%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.57.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 17.9, implying annual growth of -79.7%.
Current consensus DPS estimate is 17.5, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 24.9.

Forecast for FY24:

Moelis forecasts a full year FY24 dividend of 17.50 cents and EPS of 17.80 cents.
At the last closing share price the estimated dividend yield is 3.93%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is N/A, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ARX    AROA BIOSURGERY LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.85

Jarden rates ((ARX)) as Buy (1) –

Jarden reviews the earnings forecasts for Aroa Biosurgery off the back of 2Q22 results from Tela Bio, a company which almost exclusively sells Aroa Biosurgery's products, representing around 60% of sales.

Tela Bio has revised revenue guidance for 2022 with backlogs in hernia surgery and a pick up in market share for the hernia product.

Considering the Tela Bio update, Jarden marginally upgrades earnings forecasts for Aroa Biosurgery, however the valuation is lowered due to higher risk free rate assumptions.

Buy rating retained. Target price falls to $1.20 from $1.26.

This report was published on August 11, 2022.

Target price is $1.20 Current Price is $0.85 Difference: $0.35
If ARX meets the Jarden target it will return approximately 41% (excluding dividends, fees and charges).
The company's fiscal year ends in March.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 2.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 34.00.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 106.25.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

BRG    BREVILLE GROUP LIMITED

Household & Personal Products – Overnight Price: $22.83

Jarden rates ((BRG)) as Initiation of coverage with Neutral (3) –

Jarden initiates coverage of Breville Group with a Neutral rating and a $22 price target.

The broker views the long term growth outlook as positive for Breville, considered one of the leading small home appliance businesses with growth from acquisitions and new product developments, as well as an increase in at-home coffee consumption.

In the near term, Jarden points out major headwinds from slowing consumer spending, inventory levels and the efficacy of new products with a soft consumer. The weakness in consumer spending is forecast to be apparent by the 1H23, particularly from the EMEA markets.

Jarden earnings forecasts are broadly in line with consensus, and the broker is awaiting more results from new products and the resilience of otherwise of the consumer, before re-rating the stock.

This report was published on August 11, 2022.

Target price is $22.00 Current Price is $22.83 Difference: minus $0.83 (current price is over target).
If BRG meets the Jarden target it will return approximately minus 4% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $25.62, suggesting upside of 12.2%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 30.00 cents and EPS of 77.60 cents.
At the last closing share price the estimated dividend yield is 1.31%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 29.42.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 75.4, implying annual growth of 14.7%.
Current consensus DPS estimate is 29.5, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 30.3.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 35.00 cents and EPS of 87.40 cents.
At the last closing share price the estimated dividend yield is 1.53%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 26.12.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 82.9, implying annual growth of 9.9%.
Current consensus DPS estimate is 33.3, implying a prospective dividend yield of 1.5%.
Current consensus EPS estimate suggests the PER is 27.5.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CBA    COMMONWEALTH BANK OF AUSTRALIA

Banks – Overnight Price: $100.46

Goldman Sachs rates ((CBA)) as Sell (5) –

CommBank's FY22 result outpaced Goldman Sachs' forecast by 2%, thanks to a better-than-expected bad-and-doubtful debt performance in the June half. The June-half dividend of 210c also outpaced.

But the broker has moved on and spies cost-inflation and weaker fee income ahead. EPS forecasts are cut -3.4% in FY22; -3.5% in FY23 and -3.8% in FY24. 

Sell rating retained, the broker arguing that while fundamentals are strong, the share price is expensive and fundamentals do not justify the historically high price earnings ratio. Target price falls to $86.86 from $90.88.

This report was published on August 10, 2022.

Target price is $86.86 Current Price is $100.46 Difference: minus $13.6 (current price is over target).
If CBA meets the Goldman Sachs target it will return approximately minus 14% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $87.73, suggesting downside of -12.7%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 439.00 cents and EPS of 560.00 cents.
At the last closing share price the estimated dividend yield is 4.37%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.94.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 569.7, implying annual growth of -8.9%.
Current consensus DPS estimate is 422.3, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 17.6.

Forecast for FY24:

Goldman Sachs forecasts a full year FY24 dividend of 466.00 cents and EPS of 584.00 cents.
At the last closing share price the estimated dividend yield is 4.64%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.20.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 580.1, implying annual growth of 1.8%.
Current consensus DPS estimate is 436.2, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 17.3.

Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Jarden rates ((CBA)) as Neutral (3) –

CommBank's FY22 full-year result broadly met Jarden's forecasts and cash profit proved a beat, thanks to lower-than-estimated bad and doubtful debts.

While the broker expects both industry costs and margins to rise in FY23, it says the strength of CommBank's franchise should see it weather the imposts better than peers, and expects this will provide strong margin support as rates rise.

Jarden expects the bank's bad and doubtfuls will rise to 11 basis points of gross loans in FY23 and 20bp in FY24, compared with 4bp in 2022.

EPS forecasts rise 2% in FY23 and 1% in FY24. Neutral rating retained. Target price rises to $101 from $98.

This report was published on August 10, 2022.

Target price is $101.00 Current Price is $100.46 Difference: $0.54
If CBA meets the Jarden target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $87.73, suggesting downside of -12.7%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 408.00 cents and EPS of 542.00 cents.
At the last closing share price the estimated dividend yield is 4.06%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.54.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 569.7, implying annual growth of -8.9%.
Current consensus DPS estimate is 422.3, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 17.6.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 411.00 cents and EPS of 542.90 cents.
At the last closing share price the estimated dividend yield is 4.09%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 580.1, implying annual growth of 1.8%.
Current consensus DPS estimate is 436.2, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 17.3.

Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CGC    COSTA GROUP HOLDINGS LIMITED

Agriculture – Overnight Price: $2.81

Goldman Sachs rates ((CGC)) as Buy (1) –

Goldman Sachs shaves Costa Group's target price to $3.60 from $3.65 heading into the August 26 result. Buy rating retained.

This report was published on August 10, 2022.

Target price is $3.60 Current Price is $2.81 Difference: $0.79
If CGC meets the Goldman Sachs target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $3.19, suggesting upside of 13.3%(ex-dividends)
The company's fiscal year ends in December.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 10.00 cents and EPS of 17.00 cents.
At the last closing share price the estimated dividend yield is 3.56%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.53.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 14.1, implying annual growth of 48.9%.
Current consensus DPS estimate is 10.1, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 19.9.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 12.00 cents and EPS of 21.00 cents.
At the last closing share price the estimated dividend yield is 4.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.38.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 18.8, implying annual growth of 33.3%.
Current consensus DPS estimate is 12.5, implying a prospective dividend yield of 4.4%.
Current consensus EPS estimate suggests the PER is 14.9.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CNI    CENTURIA CAPITAL GROUP

Diversified Financials – Overnight Price: $1.96

Goldman Sachs rates ((CNI)) as Neutral (3) –

Centuria Capital's FY22 EPS forecasts met Goldman Sachs' expectations, thanks to higher performance fees, organic and inorganic growth in property funds management and strong co-investment earnings. Assets under management rose 18% to $20.6bn.

While recurring revenue as a percentage of revenue fell to 89% from 92% in FY21, Goldman Sachs expects the ratio will continue to grow, which ameliorates the earnings impact of non-recurring performance income.

Operating EPS guidance met the broker's forecasts, and the $2.1bn pipeline is weighted heavily towards healthcare.

Gearing rose sharply to 13.2% from 3.9%. Cash was $339m and 56% of the debt was hedged with a weighted average debt duration of 2.5 years.

Earnings forecasts fall -6% in FY23 and -8% in FY24. Neutral rating retained. Target price falls to $2.18 from $2.43.

This report was published on August 10, 2022.

Target price is $2.18 Current Price is $1.96 Difference: $0.22
If CNI meets the Goldman Sachs target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $2.30, suggesting upside of 17.3%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 11.60 cents and EPS of 14.00 cents.
At the last closing share price the estimated dividend yield is 5.92%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 14.3, implying annual growth of N/A.
Current consensus DPS estimate is 11.5, implying a prospective dividend yield of 5.9%.
Current consensus EPS estimate suggests the PER is 13.7.

Forecast for FY24:

Goldman Sachs forecasts a full year FY24 EPS of 15.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.07.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 15.0, implying annual growth of 4.9%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 6.1%.
Current consensus EPS estimate suggests the PER is 13.1.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Jarden rates ((CNI)) as Buy (1) –

Centuria Capital's FY22 earnings met guidance but fell -1.3% shy of consensus and -1.8% short of Jarden's forecasts.

Guidance appears to be flat but the broker notes management at the REIT is often conservative and small wins can offer strong earnings leverage.

Jarden appreciates the balance sheet, noting the company has room to co-invest where opportunities present, but would also appreciate long-term gearing disclosure.

EPS forecasts fall -4% in FY23 and -5% for FY24.

Buy rating retained after a recent upgrade, but Jarden says Centuria Capital will need to deploy that capital to be worthy. Target price falls to $2.75 from $2.90.

This report was published on August 10, 2022.

Target price is $2.75 Current Price is $1.96 Difference: $0.79
If CNI meets the Jarden target it will return approximately 40% (excluding dividends, fees and charges).
Current consensus price target is $2.30, suggesting upside of 17.3%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 11.60 cents and EPS of 14.50 cents.
At the last closing share price the estimated dividend yield is 5.92%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.52.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 14.3, implying annual growth of N/A.
Current consensus DPS estimate is 11.5, implying a prospective dividend yield of 5.9%.
Current consensus EPS estimate suggests the PER is 13.7.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 12.00 cents and EPS of 14.90 cents.
At the last closing share price the estimated dividend yield is 6.12%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.15.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 15.0, implying annual growth of 4.9%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 6.1%.
Current consensus EPS estimate suggests the PER is 13.1.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CSL    CSL LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $293.24

Goldman Sachs rates ((CSL)) as Neutral (3) –

Goldman Sachs says CSL's Vifor acquisition provides exposure to anaemia management and the $25bn chronic kidney disease market.

The broker believes this offers three main areas of additional value given 90% of chronic kidney disease sufferers are ignorant of their condition: improved awareness; earlier intervention for nephrology care; and extending sufferer's lives by slowing disease progression.

The deal is 10% to 12% accretive, estimates the broker, although the amortisation profile is unclear.

Meanwhile, Goldman Sachs spies a margin recover for Behring to pre-covid levels by 2024, noting pricing has rarely been so favourable and donor fees are falling.

Neutral rating retained. Target price is $307.

This report was published on August 10, 2022.

Target price is $307.00 Current Price is $293.24 Difference: $13.76
If CSL meets the Goldman Sachs target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $322.32, suggesting upside of 9.9%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 290.40 cents and EPS of 680.84 cents.
At the last closing share price the estimated dividend yield is 0.99%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 43.07.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 696.9, implying annual growth of N/A.
Current consensus DPS estimate is 301.9, implying a prospective dividend yield of 1.0%.
Current consensus EPS estimate suggests the PER is 42.1.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 352.93 cents and EPS of 810.06 cents.
At the last closing share price the estimated dividend yield is 1.20%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 36.20.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 819.3, implying annual growth of 17.6%.
Current consensus DPS estimate is 354.3, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 35.8.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

DXI    DEXUS INDUSTRIA REIT

REITs – Overnight Price: $2.89

Moelis rates ((DXI)) as Buy (1) –

Moelis notes Dexus Industria REIT has delivered funds from operations for FY22 of 18.5 cents per unit, at the upper end of guidance, and has issued guidance for FY23 of 16.7-17.5 cents per unit, implying a -5-10% decline in the coming year.

The broker highlighted the business park portfolio occupancy declined in the first half to 68%, creating a drag on earnings, but Moelis notes potential for upside leasing revisions at Building A.

The broker has lowered earnings estimates to account for a higher cost of debt and slow development pipeline rollout. The Buy rating is retained and the target price decreases to $3.45 from $3.54.

This report was published on August 10, 2022.

Target price is $3.45 Current Price is $2.89 Difference: $0.56
If DXI meets the Moelis target it will return approximately 19% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Moelis forecasts a full year FY23 dividend of 16.40 cents and EPS of 17.80 cents.
At the last closing share price the estimated dividend yield is 5.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.24.

Forecast for FY24:

Moelis forecasts a full year FY24 dividend of 17.00 cents and EPS of 18.70 cents.
At the last closing share price the estimated dividend yield is 5.88%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.45.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

GNC    GRAINCORP LIMITED

Agriculture – Overnight Price: $8.02

Bell Potter rates ((GNC)) as Hold (3) –

GrainCorp has updated FY22 guidance to account for a -$7m impairment charge for UMG, nearly half Bell Potter's forecast of -$13m.

The broker observes pricing conditions have continued to deteriorate since May, previously buoyant wheat prices slumping -25% and domestic exports falling -11%; plus domestic oilseed prices have retreated -13%.

Hold rating retained. Target price falls to $8.55 from $9.

This report was published on August 11, 2022.

Target price is $8.55 Current Price is $8.02 Difference: $0.53
If GNC meets the Bell Potter target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $9.65, suggesting upside of 20.3%(ex-dividends)
The company's fiscal year ends in September.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 60.00 cents and EPS of 176.20 cents.
At the last closing share price the estimated dividend yield is 7.48%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 4.55.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 170.2, implying annual growth of 179.2%.
Current consensus DPS estimate is 85.9, implying a prospective dividend yield of 10.7%.
Current consensus EPS estimate suggests the PER is 4.7.

Forecast for FY23:

Bell Potter forecasts a full year FY23 dividend of 44.00 cents and EPS of 101.40 cents.
At the last closing share price the estimated dividend yield is 5.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.91.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 98.5, implying annual growth of -42.1%.
Current consensus DPS estimate is 53.8, implying a prospective dividend yield of 6.7%.
Current consensus EPS estimate suggests the PER is 8.1.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

LOT    LOTUS RESOURCES LIMITED

Mining – Overnight Price: $0.24

Canaccord Genuity rates ((LOT)) as Speculative Buy (1) –

Canaccord Genuity is becoming more bullish about the ultimate potential of Lotus Resources' Kayelekera uranium project after the definitive feasibility study reaffirmed potential to quickly deliver product into an in-deficit market.

The company is currently evaluating its funding options, which could take the form of debt, explains the analyst.

The Speculative Buy rating is retained, while the target slips to $0.40 from $0.45 given the inflationary backdrop.

This report was published on August 12, 2022.

Target price is $0.40 Current Price is $0.24 Difference: $0.16
If LOT meets the Canaccord Genuity target it will return approximately 67% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Canaccord Genuity forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 60.00.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 60.00.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MGR    MIRVAC GROUP

Infra & Property Developers – Overnight Price: $2.18

Jarden rates ((MGR)) as Underweight (4) –

Jarden assesses the Mirvac Group results were in line with expectations and consensus forecasts. The 2.6% EPS guidance for FY23 was highlighted as robust in the context of the REIT sector, but below the broker's and consensus expectations.

The analyst views Mirvac Group as offering a mixed outlook. Residential is forecast to be reaching peak cycle with settlement forecasts for FY24 and FY25, forecast to be lower than the FY23 estimate of 2598 (2500 guidance).

With 47% of earnings generated from Commercial, Jarden is concerned about the outlook for the Office sector where Mirvac Group is most highly exposed.

Underweight maintained for Mirvac Group. Target is reduced to $2.30 from $2.40 from an adjustment in the valuation.

This report was published on August 12, 2022.

Target price is $2.30 Current Price is $2.18 Difference: $0.12
If MGR meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $2.47, suggesting upside of 13.1%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 10.90 cents and EPS of 15.50 cents.
At the last closing share price the estimated dividend yield is 5.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.06.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 15.0, implying annual growth of -34.8%.
Current consensus DPS estimate is 10.6, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 14.5.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 11.30 cents and EPS of 15.80 cents.
At the last closing share price the estimated dividend yield is 5.18%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.80.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 15.0, implying annual growth of N/A.
Current consensus DPS estimate is 11.0, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 14.5.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MNY    MONEY3 CORPORATION LIMITED

Business & Consumer Credit – Overnight Price: $2.29

Bell Potter rates ((MNY)) as Buy (1) –

Following a change of analyst at Bell Potter, the target for Money3 is lowered to $3.22 from $4.60 after allowances are made for a slowing economy. Assumptions for lower loan growth are lowered, while higher interest rates and bad debts are expected.

The broker feels the share price is discounting far too much bad news and retains its Buy rating.

Up until now, loan book growth has been helped by the strong economy, low levels of unemployment and the strength of used car prices, explains the analyst. It's noted a common reason for new loans is customers' need for a reliable car to get to work.

FY22 results are due on Tuesday August 16.

This report was published on August 12, 2022.

Target price is $3.22 Current Price is $2.29 Difference: $0.93
If MNY meets the Bell Potter target it will return approximately 41% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 12.00 cents and EPS of 24.40 cents.
At the last closing share price the estimated dividend yield is 5.24%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.39.

Forecast for FY23:

Bell Potter forecasts a full year FY23 dividend of 10.70 cents and EPS of 22.10 cents.
At the last closing share price the estimated dividend yield is 4.67%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.36.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MYX    MAYNE PHARMA GROUP LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.38

Wilsons rates ((MYX)) as Overweight (1) –

Wilsons is positive about the sale of the Metrics Contract Services (MCS) business by Mayne Pharma and assesses management can now focus on the delivery and execution of the branded oral contraceptive Nextstellis, to "fill the hole" as left by the divestment of MCS.

Equally, the broker is upbeat about the deleveraging of the balance sheet, including the removal of $300m in net debt, with optionality to reward shareholders and pursue growth opportunities.

The broker's earnings forecasts remove MCS from mid 1H223. There are no changes to FY22 earnings, with FY23 earnings cut by -13%.

An Overweight rating is retained and the target price adjusts to $0.61 from $0.32 for the change in the discounted cashflow post the MCS sale.

This report was published on August 12, 2022.

Target price is $0.61 Current Price is $0.38 Difference: $0.23
If MYX meets the Wilsons target it will return approximately 61% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Wilsons forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 2.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.27.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 1.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 27.14.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

NCZ    NEW CENTURY RESOURCES LIMITED

Zinc & Lead – Overnight Price: $1.85

Shaw and Partners rates ((NCZ)) as Initiation of coverage with Buy (1) –

Shaw and Partners initiates coverage on New Century Resources. The broker notes the company's flagship project, Queensland's Century zinc site, is the largest remining and processing operation in Australia.

The company is working to develop additional underground and open pit operations.

The broker finds Century logistically strategic, with the site offering an underground pipeline to the Karumba port facility for shipping of concentrate to smelters, which should support logistics involved with a new discovery within 100km of the existing site.

Shaw and Partners also highlights New Century Resources' focus on future facing commodities and clean energy metals including copper and silver, positioning itself to supply minerals for a low carbon economy. 

The broker initiates with a Buy rating and a target price of $3.60. 

This report was published on August 11, 2022.

Target price is $3.60 Current Price is $1.85 Difference: $1.75
If NCZ meets the Shaw and Partners target it will return approximately 95% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of 5.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 34.26.

Forecast for FY23:

Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of 22.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.19.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

NIC    NICKEL INDUSTRIES LIMITED

Nickel – Overnight Price: $1.14

Bell Potter rates ((NIC)) as Buy (1) –

To help fund Nickel Industries' 70% new equity interest in the Oracle Nickel Project in Indonesia, the company has raised US$225m via the issue of corporate debt securities.

The broker believes Nickel Industries has a very strong liquidity buffer (over US$600m) against the remaining funding requirements for the Oracle Nickel Project acquisition.

A higher net debt position lowers the analyst's target price by -6% to $1.96. The Buy rating is maintained.

This report was published on August 12, 2022.

Target price is $1.96 Current Price is $1.14 Difference: $0.82
If NIC meets the Bell Potter target it will return approximately 72% (excluding dividends, fees and charges).
Current consensus price target is $1.60, suggesting upside of 40.4%(ex-dividends)
The company's fiscal year ends in December.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 6.95 cents and EPS of 16.26 cents.
At the last closing share price the estimated dividend yield is 6.09%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.01.

Forecast for FY23:

Bell Potter forecasts a full year FY23 dividend of 12.51 cents and EPS of 31.26 cents.
At the last closing share price the estimated dividend yield is 10.97%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 3.65.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 18.1, implying annual growth of 34.1%.
Current consensus DPS estimate is 8.9, implying a prospective dividend yield of 7.8%.
Current consensus EPS estimate suggests the PER is 6.3.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

NUF    NUFARM LIMITED

Agriculture – Overnight Price: $5.32

Bell Potter rates ((NUF)) as Buy (1) –

Bell Potter raises its FY22 profit estimate for Nufarm by around 3% to reflect stronger peer reporting and a lower Australian dollar in the first half of 2022.

Beyond FY22, the analyst still expects a normalisation in European and North American conditions, and initial contributions from Carinata and Omega-3 (ingredient in aquaculture feed) to support higher earnings.

Nufarm's Carinata is a sustainable low carbon biofuel feedstock. The target rises to $6.75 from $6.65 and the Buy rating is unchanged.

This report was published on August 12, 2022.

Target price is $6.75 Current Price is $5.32 Difference: $1.43
If NUF meets the Bell Potter target it will return approximately 27% (excluding dividends, fees and charges).
Current consensus price target is $6.87, suggesting upside of 29.2%(ex-dividends)
The company's fiscal year ends in September.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 8.00 cents and EPS of 33.20 cents.
At the last closing share price the estimated dividend yield is 1.50%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.02.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 36.1, implying annual growth of 137.5%.
Current consensus DPS estimate is 8.5, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 14.7.

Forecast for FY23:

Bell Potter forecasts a full year FY23 dividend of 9.00 cents and EPS of 36.50 cents.
At the last closing share price the estimated dividend yield is 1.69%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.58.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 31.9, implying annual growth of -11.6%.
Current consensus DPS estimate is 9.3, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 16.7.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

OFX    OFX GROUP LIMITED

Diversified Financials – Overnight Price: $2.63

Wilsons rates ((OFX)) as Overweight (1) –

Wilsons considers the 1Q23 results for OFX Group as a "beat" and better than expectations, noting Firma reported stronger growth.

The broker is looking to the July/August trading update for confirmation of the better than anticipated results to upgrade earnings forecasts.

Of note, corporate performance has remained firm and there are some changes in consumer uses to Travel from Overseas Property, the broker observes.

The Overweight rating is retained and the target price decreases to $3.05 from $3.06.

This report was published on August 12, 2022.

Target price is $3.05 Current Price is $2.63 Difference: $0.42
If OFX meets the Wilsons target it will return approximately 16% (excluding dividends, fees and charges).
The company's fiscal year ends in March.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 0.00 cents and EPS of 12.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.87.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 13.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.34.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

QBE    QBE INSURANCE GROUP LIMITED

Insurance – Overnight Price: $12.07

Jarden rates ((QBE)) as Buy (1) –

Jarden views the QBE Insurance 1H22 earnings results as positive and adjusted earnings were better than expectations and consensus.

The broker points strong growth in written premiums and a lower expense ratio, while the North American operations posted underwriting profits ex-Crop, indicating the turnaround seems in place. 

Broker earnings forecasts are adjusted 14.4% for FY22 and 2.8% for FY23.

The Buy rating is maintained and QBE Insurance remains the broker's top pick in the General Insurance sector, on valuation grounds with the target price raised to $17 from $16.

This report was published on August 11, 2022.

Target price is $17.00 Current Price is $12.07 Difference: $4.93
If QBE meets the Jarden target it will return approximately 41% (excluding dividends, fees and charges).
Current consensus price target is $15.72, suggesting upside of 30.3%(ex-dividends)
The company's fiscal year ends in December.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 75.03 cents and EPS of 81.42 cents.
At the last closing share price the estimated dividend yield is 6.22%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.82.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 76.7, implying annual growth of N/A.
Current consensus DPS estimate is 54.7, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 15.7.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 100.04 cents and EPS of 142.42 cents.
At the last closing share price the estimated dividend yield is 8.29%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.47.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 138.5, implying annual growth of 80.6%.
Current consensus DPS estimate is 98.8, implying a prospective dividend yield of 8.2%.
Current consensus EPS estimate suggests the PER is 8.7.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

SBM    ST. BARBARA LIMITED

Gold & Silver – Overnight Price: $1.06

Shaw and Partners rates ((SBM)) as Buy (1) –

Shaw and Partners notes St. Barbara's Atlantic Gold has received an important regulatory permit that will allow operations to continue into FY23. The broker highlights the approval will allow construction to commence in coming weeks.

With further clarity around Atlantic Gold's FY23 production, St. Barbara has released guidance for the coming year, pointing to gold production of 280-315,000 ounces at an all in sustaining cost of $2,050-2,150 per ounce.

The Buy rating and target price of $1.80 are retained.

This report was published on August 11, 2022.

Target price is $1.80 Current Price is $1.06 Difference: $0.74
If SBM meets the Shaw and Partners target it will return approximately 70% (excluding dividends, fees and charges).
Current consensus price target is $1.16, suggesting upside of 9.7%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of 3.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.29.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.2, implying annual growth of N/A.
Current consensus DPS estimate is 0.5, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 48.2.

Forecast for FY23:

Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of 8.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.18.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.7, implying annual growth of 22.7%.
Current consensus DPS estimate is 1.0, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 39.3.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBI    UNIVERSAL BIOSENSORS INC

Medical Equipment & Devices – Overnight Price: $0.30

Canaccord Genuity rates ((UBI)) as Speculative Buy (1) –

Short-term issues across each of Universal Biosensors's three divisions caused delays in delivery and saw the company deliver a miss on Canaccord Genuity's first half expectations. 

Universal Biosensors reported revenue of $3.1m, compared to the broker's anticipated $3.3m. Combined with a gross profit miss of -17% and operating expenditure miss of -7.5%, an earnings loss of -$7.5m exceeded Canaccord Genuity's forecast by -$0.9m.

The broker is anticipating a more positive second quarter as issues resolve, but has taken a more cautious approach with forecasts. Revenue and gross profit estimates decrease -10% while operating expenditure increases 11% in FY22.

The Speculative Buy rating is retained and the target price decreases to $0.67 from $0.72.

This report was published on August 11, 2022.

Target price is $0.67 Current Price is $0.30 Difference: $0.37
If UBI meets the Canaccord Genuity target it will return approximately 123% (excluding dividends, fees and charges).
The company's fiscal year ends in December.

Forecast for FY22:

Canaccord Genuity forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 8.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 3.61.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 1.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 15.79.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface. This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

As part of emerging new trends overseas, The Australian Broker Call *Extra* Edition also includes providers of sponsored research. Readers should bear in mind, sponsored research, while not necessarily of lower quality, has the embedded complication that the company that is the subject of the research has paid for this research. Providers of sponsored research that can potentially be included in this Report are Breakaway Research, Edison Investment Research, Independent Investment Research, NDF Research, Pitt Street Research, and TMT Analytics.

Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.

Click to view our Glossary of Financial Terms